^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TBX-2400

    i
    Other names: TBX-2400
    Associations

    News

    Trials
    Company:
    Taiga Biotech
    Drug class:
    Stem cell replacement
    Associations

    News

    Trials
    over4years
    Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Taiga Biotechnologies, Inc. | Initiation date: Jun 2021 --> Dec 2021
    Clinical • Trial initiation date
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    TBX-2400
    almost5years
    Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Taiga Biotechnologies, Inc. | Initiation date: Mar 2021 --> Jun 2021
    Clinical • Trial initiation date
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    TBX-2400
    5years
    Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Taiga Biotechnologies, Inc.
    Clinical • New P1 trial
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C)
    |
    TBX-2400